USPTO serial 79333598
MBDNA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- BLANE, SUZANNE
- Law office
- TMO LAW OFFICE 114 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with MBDNA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations, enzymes and DNA for the preparation of nucleic acid for scientific research; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific and research use; DNA extracts for use in agri-biotechnology and nanotechnology; nucleic acids comprising natural and unnatural nucleotides for use in nanotechnology applications including data storage, data retrieval and computing; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for use in nanotechnology applications including data storage, data retrieval and computing; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for use in nanotechnology applications including data storage, data retrieval and computing; nucleic acid analogues with organic and inorganic chemicals for laboratory use in labelling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for laboratory use in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for laboratory use in creating nanostructures and scaffolds; nucleic acids comprising natural and unnatural nucleotides for scientific and research purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for scientific and research purposes; all the aforesaid goods for use in nanotechnology applications including data storage, data retrieval and computing for scientific and research purposes; nucleic acids or nucleic acid analogues for labelling, imaging and sensing applications for scientific and research purposes; nucleic acids or nucleic acid analogues as smart materials for scientific and research purposes; two-dimensional and three-dimensional nucleic acids or nucleic acid analogues for creating nanostructures and scaffolds for scientific and research purposes | ACTIVE | — |
| 005 | Vaccines; DNA based vaccines; DNA extracts, namely, nucleic acid sequences and chemical reagents for medical use; therapeutic DNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labelling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffolds; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; all the aforesaid goods for use in nanotechnology applications including data storage, data retrieval and computing for medical and veterinary purposes; nucleic acids or nucleic acid analogues for labelling, imaging and sensing applications for medical and veterinary purposes; nucleic acids or nucleic acid analogues as smart materials for medical and veterinary purposes; two-dimensional and three-dimensional nucleic acids or nucleic acid analogues for creating nanostructures and scaffolds for medical and veterinary purposes | ACTIVE | — |
| 009 | Electronic components and applications including wires, semi-conductors including transistors, rectifiers, diodes including light emitting diodes and systems for energy storage such as batteries all comprising of nucleic acids or nucleic acid analogues; parts and fittings for all the aforesaid technology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 4, 2024 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 12, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 11, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 6, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 19, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 19, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 13, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 11, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 11, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 17, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 24, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 24, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 28, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 26, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 22, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 17, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |